Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis

Li, Mei; Zhang, Zhenlin; Liao, Er-Yuan; Chen, Decai; Liu, Jian; Tu, Tao; Wang, Wen; Xia, Weibo; Lu, Yujuan; Sheng, Zhifeng; Lu, Chin‐Song; Meng, Guo-ling; Xu, Liang; Zhang, Weijie; Hu, Yingying; Xu, Li

doi:10.1097/gme.0b013e31825fe2e8

Cited by 8 publications

(10 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Because no difference existed in baseline BMD and the percentage changes after 12 months of treatment between low and standard dosage groups [26], the effects of two dosages of alendronate were similar. In order to avoid the influence of small sample size, we put the two groups together as one sample to analyze the influence of SOST gene polymorphisms on BMD and the response to alendronate.…”

Section: Baseline Characteristics Of Participants and Effect Of Alendromentioning

confidence: 86%

SOST polymorphisms and response to alendronate treatment in postmenopausal Chinese women with osteoporosis

Zhou

Zhang

et al. 2015

Pharmacogenomics

Self Cite

View full text Add to dashboard Cite

Aim:To investigate the association between SOST gene polymorphisms and response to alendronate treatment. Materials & methods: 639 Chinese postmenopausal women with osteoporosis or osteopenia received alendronate treatment. Polymorphisms of SOST were analyzed. Bone mineral density (BMD), serum ALP and β-CTX levels were measured. The correlation of SOST polymorphisms with changes of BMD and bone biomarkers after treatment was analyzed. Results: rs1234612 and rs851054 polymorphisms were correlated to baseline lumbar spine BMD (p < 0.05). After 12 months of treatment rs1234612 and rs865429 polymorphisms were correlated to BMD changes at the lumbar spine (p < 0.05) or femoral neck (p < 0.05), respectively. Conclusion: The polymorphisms of SOST are genetic factors affecting bone health and response to alendronate in Chinese postmenopausal women.

show abstract

Section: Baseline Characteristics Of Participants and Effect Of Alendromentioning

confidence: 86%

SOST polymorphisms and response to alendronate treatment in postmenopausal Chinese women with osteoporosis

Zhou

Zhang

et al. 2015

Pharmacogenomics

Self Cite

View full text Add to dashboard Cite

show abstract

“…In addition, responsiveness to anti-resorptive effects differs between the Asian population and the white population, possibly owing to genetic, dietary, and environmental differences. [ 7 8 9 ] Hence, we propose a potential algorithm to guide physicians in South Korea, despite no available clear recommendations regarding the length of use and drug holidays based on the current research. These statements cannot and should not be used to govern health policy decisions about reimbursement or the availability of services.…”

Section: Introductionmentioning

confidence: 99%

Position Statement: Drug Holiday in Osteoporosis Treatment with Bisphosphonates in South Korea

et al. 2015

View full text Add to dashboard Cite

Bisphosphonates have been widely used in the treatment of osteoporosis with robust data from many placebo-controlled trials demonstrating its efficacy in fracture risk reduction over 3 to 5 years of treatment. Although bisphosphonates are generally safe and well tolerated, concerns have emerged about the adverse effects related to its long-term use, including osteonecrosis of the jaw and atypical femur fractures. Because bisphosphonates are incorporated into the skeleton and continue to exert an anti-resorptive effect for a period of time after the discontinuation of drugs, the concept of a "drug holiday" has emerged, whereby the risk of adverse effects might be decreased while the patient still benefits from anti-fracture efficacy. As randomized clinical trial evidence is not yet available on who may qualify for a drug holiday, there is considerable controversy regarding the selection of candidates for the drug holiday and monitoring during a drug holiday, both of which should be based on individual assessments of risk and benefit. This statement will provide suggestions for clinicians in South Korea on the identification of possible candidates and monitoring during a bisphosphonate drug holiday.

show abstract

“…For these reasons, a low-dose therapy could be considered for elderly women, especially those who are at a higher risk of developing oversuppression of bone turnover. Previous studies usually included postmenopausal women with an average age of 60 years 17,18,20) ; however, all our patients were over 70 years of age and had many comorbidities. As we are in the midst of an aging society, this report provides useful clinical information to guide the prescription of bisphosphonates for elderly Korean women.…”

Section: Discussionmentioning

confidence: 99%

“…Another study also showed that a half dose of alendronate (70 mg every 2 weeks) improved the percent change in BMD, and there was no significant difference from the effect induced by the standard dose (70 mg weekly) 20) . Here, we report our experience with the use of low-dose bisphosphonates, which is the conventional weekly bisphosphonate dose but is administered every other week, in 7 elderly women with osteoporosis to investigate whether the lower dose was effective in improving BMD and suppressing bone turnover markers.…”

Section: Introductionmentioning

confidence: 98%

“…Furthermore, it is recommended that bisphosphonate therapy be continued in patients who still have lower BMD and are at a high risk of fractures despite of long-term bisphosphonate use 16) . There are only a limited numbers of studies that have reported comparable effects between the administration of low-dose and conventional dose of bisphosphonates [17][18][19][20] .…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Effects of Low-Dose Bisphosphonate Treatment on Bone Mineral Density and Bone Turnover Markers in Elderly Patients With Osteoporosis

Lee¹,

Kim²,

Kong³

et al. 2016

Ann Geriatr Med Res

View full text Add to dashboard Cite

Background: Osteoporosis is commonly treated with bisphosphonates. These drugs promote osteoclast apoptosis, which suppresses bone resorption. However, the probability of side effects increases with long-term use of bisphosphonates. There are several reports in Asia that show comparable effects between low and conventional doses of bisphosphonates; however, such reports are lacking in Korea. Here, we report a case series of 7 patients with osteoporosisall women aged over 70 years -who were treated with bisphosphonates administered every other week. Methods: Patients who had been diagnosed with osteoporosis and treated with a less frequent dose of bisphosphonates at a tertiary university hospital from January 2010 to May 2016 were included in this study. Bone mineral density (BMD) was assessed at the baseline and at a 12-month interval after the first administration of low-dose bisphosphonates by using dual-energy X-ray absorptiometry. The bone turnover marker C-terminal telopeptide (CTX) was evaluated at 3, 6, and 12 months after the first administration. Results: After 12 months of treatment with a lower dose of bisphosphonates, BMD increased and CTX levels were suppressed. The mean change in BMD was 4.0% at the lumbar spine, 3.1% at the femur neck, and 1.5% at the total hip; CTX was suppressed by 34% at 3 months, 42% at 6 months, and 44% at the end of the treatment. Conclusion: We found that low-dose bisphosphonate therapy improved BMD and suppressed bone turnover rates in elderly Korean women.

show abstract

Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis

Cited by 8 publications

References 18 publications

SOST polymorphisms and response to alendronate treatment in postmenopausal Chinese women with osteoporosis

SOST polymorphisms and response to alendronate treatment in postmenopausal Chinese women with osteoporosis

Position Statement: Drug Holiday in Osteoporosis Treatment with Bisphosphonates in South Korea

The Effects of Low-Dose Bisphosphonate Treatment on Bone Mineral Density and Bone Turnover Markers in Elderly Patients With Osteoporosis

Contact Info

Product

Resources

About